Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
WASHINGTON & SAN FRANCISCO--(BUSINESS WIRE)--REGENX Biosciences, LLC and Audentes Therapeutics, Inc. announce that they have entered into an agreement for the development and commercialization of products to treat X-Linked Myotubular Myopathy (XLMTM) and Pompe disease using NAV vectors.
Help employers find you! Check out all the jobs and post your resume.
